Aurobindo Pharma’s CuraTeQ Biologics has mutually terminated its biosimilar agreement with BioFactura for BFI-751, citing portfolio prioritisation, with the company saying the move will not impact its broader biosimilars strategy.
Aurobindo Pharma’s CuraTeQ Biologics has mutually terminated its biosimilar agreement with BioFactura for BFI-751, citing portfolio prioritisation, with the company saying the move will not impact its broader biosimilars strategy.